Comparing Allergist and Cardiologist Considerations for the Optimal Management of Thienopyridines Hypersensitivity

Gianfanco Calogiuri, Alessandro Mandurino-Mirizzi, Claudio Parlangeli, Luigi Macchia, Caterina Foti, Michael P Savage

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND OBJECTIVE: The thienopyridine family includes ticlopidine, clopidogrel and prasugrel which are antiplatelet drugs largely used, mainly associated to aspirin, for treatment of acute coronary syndromes and after percutaneous coronary interventions, to avoid thrombosis. In some patients, thienpyridines may cause hypersensitivity reactions which jeopardize the optimal therapeutic and preventive approach to vascular diseases. The management of thienopyridine hypersensitivity seems to be best done as an interdisciplinary collaboration between the allergist and cardiologist.

METHOD: The present study investigates the management of thienopyridines hypersensitivity on the basis of published case reports and studies, comparing the pro and contro of pharmacological treatments, different desensitization protocols to thienopyridines and substitution of antiplatelet agents eaches others, according to the point of view of cardiologist and allergist. For the cardiologist, the important issues are the necessity of continuing therapy, the desired duration of therapy based on the clinical indication of the individual patient and appropriateness of using one of the alternative P2Y12 inhibitors. For the allergist, the important issues are weighing the risk and benefits of the various therapeutic options: treating "through" desensitization, or switching to an alternative agent.

RESULTS AND CONCLUSION: All the data seem to suggest that only working together, a cardio-allergy team of specialists may evaluate and offer the best approach to clinical decision-making for the individual patient.

Original languageEnglish
Pages (from-to)2-12
Number of pages11
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
Volume19
Issue number1
DOIs
Publication statusPublished - 2019
Externally publishedYes

Fingerprint

Thienopyridines
Hypersensitivity
clopidogrel
Platelet Aggregation Inhibitors
Therapeutics
Ticlopidine
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Vascular Diseases
Aspirin
Cardiologists
Allergists
Thrombosis
Pharmacology

Cite this

Comparing Allergist and Cardiologist Considerations for the Optimal Management of Thienopyridines Hypersensitivity. / Calogiuri, Gianfanco; Mandurino-Mirizzi, Alessandro; Parlangeli, Claudio; Macchia, Luigi; Foti, Caterina; Savage, Michael P.

In: Endocrine, Metabolic and Immune Disorders - Drug Targets, Vol. 19, No. 1, 2019, p. 2-12.

Research output: Contribution to journalArticle

Calogiuri, Gianfanco ; Mandurino-Mirizzi, Alessandro ; Parlangeli, Claudio ; Macchia, Luigi ; Foti, Caterina ; Savage, Michael P. / Comparing Allergist and Cardiologist Considerations for the Optimal Management of Thienopyridines Hypersensitivity. In: Endocrine, Metabolic and Immune Disorders - Drug Targets. 2019 ; Vol. 19, No. 1. pp. 2-12.
@article{7ada142955304b2fa408b85f3dd00de1,
title = "Comparing Allergist and Cardiologist Considerations for the Optimal Management of Thienopyridines Hypersensitivity",
abstract = "BACKGROUND AND OBJECTIVE: The thienopyridine family includes ticlopidine, clopidogrel and prasugrel which are antiplatelet drugs largely used, mainly associated to aspirin, for treatment of acute coronary syndromes and after percutaneous coronary interventions, to avoid thrombosis. In some patients, thienpyridines may cause hypersensitivity reactions which jeopardize the optimal therapeutic and preventive approach to vascular diseases. The management of thienopyridine hypersensitivity seems to be best done as an interdisciplinary collaboration between the allergist and cardiologist.METHOD: The present study investigates the management of thienopyridines hypersensitivity on the basis of published case reports and studies, comparing the pro and contro of pharmacological treatments, different desensitization protocols to thienopyridines and substitution of antiplatelet agents eaches others, according to the point of view of cardiologist and allergist. For the cardiologist, the important issues are the necessity of continuing therapy, the desired duration of therapy based on the clinical indication of the individual patient and appropriateness of using one of the alternative P2Y12 inhibitors. For the allergist, the important issues are weighing the risk and benefits of the various therapeutic options: treating {"}through{"} desensitization, or switching to an alternative agent.RESULTS AND CONCLUSION: All the data seem to suggest that only working together, a cardio-allergy team of specialists may evaluate and offer the best approach to clinical decision-making for the individual patient.",
author = "Gianfanco Calogiuri and Alessandro Mandurino-Mirizzi and Claudio Parlangeli and Luigi Macchia and Caterina Foti and Savage, {Michael P}",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",
year = "2019",
doi = "10.2174/1871530318666180914121758",
language = "English",
volume = "19",
pages = "2--12",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Comparing Allergist and Cardiologist Considerations for the Optimal Management of Thienopyridines Hypersensitivity

AU - Calogiuri, Gianfanco

AU - Mandurino-Mirizzi, Alessandro

AU - Parlangeli, Claudio

AU - Macchia, Luigi

AU - Foti, Caterina

AU - Savage, Michael P

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

PY - 2019

Y1 - 2019

N2 - BACKGROUND AND OBJECTIVE: The thienopyridine family includes ticlopidine, clopidogrel and prasugrel which are antiplatelet drugs largely used, mainly associated to aspirin, for treatment of acute coronary syndromes and after percutaneous coronary interventions, to avoid thrombosis. In some patients, thienpyridines may cause hypersensitivity reactions which jeopardize the optimal therapeutic and preventive approach to vascular diseases. The management of thienopyridine hypersensitivity seems to be best done as an interdisciplinary collaboration between the allergist and cardiologist.METHOD: The present study investigates the management of thienopyridines hypersensitivity on the basis of published case reports and studies, comparing the pro and contro of pharmacological treatments, different desensitization protocols to thienopyridines and substitution of antiplatelet agents eaches others, according to the point of view of cardiologist and allergist. For the cardiologist, the important issues are the necessity of continuing therapy, the desired duration of therapy based on the clinical indication of the individual patient and appropriateness of using one of the alternative P2Y12 inhibitors. For the allergist, the important issues are weighing the risk and benefits of the various therapeutic options: treating "through" desensitization, or switching to an alternative agent.RESULTS AND CONCLUSION: All the data seem to suggest that only working together, a cardio-allergy team of specialists may evaluate and offer the best approach to clinical decision-making for the individual patient.

AB - BACKGROUND AND OBJECTIVE: The thienopyridine family includes ticlopidine, clopidogrel and prasugrel which are antiplatelet drugs largely used, mainly associated to aspirin, for treatment of acute coronary syndromes and after percutaneous coronary interventions, to avoid thrombosis. In some patients, thienpyridines may cause hypersensitivity reactions which jeopardize the optimal therapeutic and preventive approach to vascular diseases. The management of thienopyridine hypersensitivity seems to be best done as an interdisciplinary collaboration between the allergist and cardiologist.METHOD: The present study investigates the management of thienopyridines hypersensitivity on the basis of published case reports and studies, comparing the pro and contro of pharmacological treatments, different desensitization protocols to thienopyridines and substitution of antiplatelet agents eaches others, according to the point of view of cardiologist and allergist. For the cardiologist, the important issues are the necessity of continuing therapy, the desired duration of therapy based on the clinical indication of the individual patient and appropriateness of using one of the alternative P2Y12 inhibitors. For the allergist, the important issues are weighing the risk and benefits of the various therapeutic options: treating "through" desensitization, or switching to an alternative agent.RESULTS AND CONCLUSION: All the data seem to suggest that only working together, a cardio-allergy team of specialists may evaluate and offer the best approach to clinical decision-making for the individual patient.

U2 - 10.2174/1871530318666180914121758

DO - 10.2174/1871530318666180914121758

M3 - Article

VL - 19

SP - 2

EP - 12

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

IS - 1

ER -